Breye Therapeutics ApS: Financial statements 2021
CVR: 40279865
Source: annual report 2021, Danish Business Authority
01/04/2020 – 31/03/2021
Breye Therapeutics ApS (CVR 40279865) has filed annual accounts for 2021. In 2021, the company reported a gross profit of DKK -67,528 and a net result of DKK -289,668. Equity in the 2021 report amounted to DKK 28,261. The solvency ratio was 0.2%. The company had 1 employee in the financial year.
- Gross Profit
- DKK -67,528
- Profit/Loss
- DKK -289,668
- Equity
- DKK 28,261
- Total Assets
- DKK 14,174,229
- Employees
- 1
Official annual report
Find more companies like Breye Therapeutics ApS
Build lead lists with filters on industry, geography, size and financials — and export straight to Excel.
Try the lead list generatorAbout Breye Therapeutics ApS
Breye Therapeutics ApS is a Danish company of the type Anpartsselskab based in Hørsholm, founded in 2019. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named Ciana Therapeutics ApS and Visus Therapeutics ApS. The management consists of Ulrik Mouritzen. The board consists of Jimmy Arnold V Van Heusden (chair), Carl Johan Kördel, Chiara Rossana Maria Liberati and Gabriela Burian. The company's owners include Novo Holdings A/S, Visus Holding ApS and BII Holdings A/S. The company has 3 employees (2026). In 2026, the company reported a gross profit of DKK -7,655,438 and a net result of DKK -85,575,302 compared with DKK -89,139,846 the year before. Equity in the 2026 report amounted to DKK -126,213,092.